

United States Patent and Trademark Office

.UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

151

7590

01/27/2003

HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT 340 KINGSLAND STREET NUTLEY, NJ 071 I0 EXAMINER

DEBERRY, REGINA M

ART UNIT

CLASS-SUBCLASS

1647

530-397000

DATE MAILED: 01/27/2003

APPLICATION NO. FILING OATE . FIRST NAMEO INVENTOR ATTORNEY OOCKET NO. CONFIRMATION NO.

09/604.938 06/27/2000 Pascal Sebastian Balion 1097 5229

TITLE OF INVENTION: ERYTHROPOIETIN CONJUGATES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) OUE	OATE OUE
nonprovisional	NO	\$1300	\$0	\$1300	04/28/2003

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and I/2 the ISSUE FEE shown above.


Applicant claims SMALL ENTITY status.
 See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.





Complete and send this form, together with applicable fee(s), to: Mail Box ISSUE FEE

Commissioner for Patents Washington, D.C. 20231

(703)746-4000 Fax

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) 7590 01/27/2003 151 HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT Certificate of Mailing or Transmission 340 KINGSLAND STREET

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Box Issue Fee address above, or being facsimile transmitted to the USPTO, on the date indicated below. **NUTLEY, NJ 07110** (Depositor's name (Signature) FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. 09/604.938 06/27/2000 1097 5229 Pascal Sebastian Balion TITLE OF INVENTION: ERYTHROPOIETIN CONJUGATES

APPLN, TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1300	\$0	\$1300	04/28/2003
EXAMINER		ART UNIT	CLASS-SUBCLASS		
DEBERRY, REGINA M		1647	530-397000		
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered 2		
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/I 22) attached.					
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.		attomey or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.			

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or cate	egories (will not be printed on the patent)	☐ individual	□ corporation or other private group entit	ty 🗅 government			
4a. The following fee(s) are enclosed:	4b. Payment of Fee(s):						
□ Issue Fee	A check in the amount	☐ A check in the amount of the fee(s) is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached.					
□ Publication Fee	Payment by credit card						
☐ Advance Order - # of Copies	☐ The Commissioner is h Deposit Account Number	☐ The Commissioner is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number(enclose an extra copy of this form).					
Commissioner for Patents is requested to apply the Is	sue Fee and Publication Fee (if any) or to re-	apply any previo	ously paid issue fee to the application identi	fied above.			
(Authorized Signature)	(Date)						
NOTE; The Issue Fee and Publication Fee (if req other than the applicant; a registered attorney or interest as shown by the records of the United States. This collection of information is required by 37 C obtain or retain a benefit by the public which is to application. Confidentiality is governed by 35 U.S.6 estimated to take 12 minutes to complete, including completed application form to the USPTO. Time case. Any comments on the amount of time yo	agent; or the assignee or other party in stream and Trademark Office. FR 1.311. The information is required to file (and by the USPTO to process) and 1.122 and 37 CFR 1.14. This collection is g gathering, preparing, and submitting the will vary depending upon the individual u require to complete this form and/or						
suggestions for reducing this burden, should be se Patent and Trademark Office, U.S. Department of NOT SEND FEES OR COMPLETED FORM Commissioner for Patents, Washington, DC 20231.	nt to the Chief Information Officer, U.S. Commerce, Washington, D.C. 20231. DO S TO THIS ADDRESS. SEND TO:						
Under the Paperwork Reduction Act of 1995, n collection of information unless it displays a valid C	o persons are required to respond to a DMB control number.						



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/604,938	06/27/2000	Pascal Sebastian Balion	1097	5229
151 7590 01/27/2003			EXAMIN	ER
HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT 340 KINGSLAND STREET NUTLEY, NJ 07110			DEBERRY, REGINA M	
			ART UNIT	PAPER NUMBER
			1647	
			DATE MAILED: 01/27/2003	

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The patent term adjustment to date is 60 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 60 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

Any questions regarding the patent term extension or adjustment determination should be directed to the Office of Patent Legal Administration at (703)305-1383.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE		LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/604,938 06/27/2000 151 7590 01/27/2003		6/27/2000	Pascal Sebastian Balion	1097	5229
		01/27/2003		EXAMIN	ER
HOFFMANN-LA ROCHE INC. PATENT LAW DEPARTMENT 340 KINGSLAND STREET		DEBERRY, REGINA M			
				ART UNIT	PAPER NUMBER
NUTLEY, NJ 07110				1647	
				DATE MAILED: 01/27/2003	

Notice of Fee Increase on January 1, 2003

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after January 1, 2003, then the amount due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there will be an increase in fees effective on January 1, 2003. See Revision of Patent and Trademark Fees for Fiscal Year 2003; Final Rule, 67 Fed. Reg. 70847, 70849 (November 27, 2002).

The current fee schedule is accessible from: http://www.uspto.gov/main/howtofees.htm.

If the issue fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due," but not the correct amount in view of the fee increase, a "Notice to Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice to Pay Balance of Issue Fee," if the response to the Notice of Allowance and Fee(s) due form is to be filed on or after January 1, 2003 (or mailed with a certificate of mailing on or after January 1, 2003), the issue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth Edition, August 2001).

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No.	Applicant(s)
	09/604,938	BALION, PASCAL SEBASTIAN
Notice of Allowability	Examiner	Art Unit
	Regina M. DeBerry	1647
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
 2. ☐ The allowed claim(s) is/are 3-6, 10, 11, 23-26, 61-65 (renu 3. ☐ The drawings filed on 27 June 2000 are accepted by the E 4. ☐ Acknowledgment is made of a claim for foreign priority und a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 	xaminer. Value (d) or (f). Value been received.	
2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents and the priority documents of the pr	cuments have been received in this render 35 U.S.C. § 119(e) (to a provision pplication has been received:	national stage application from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of 7. A SUBSTITUTE OATH OR DECLARATION must be subminformal patent application (PTO-152) which gives reas	this application. THIS THREE-MON	ITH PERIOD IS NOT EXTENDABLE 'S AMENDMENT OF NOTICE OF
 8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No. (b) including changes required by the proposed drawing of including changes required by the attached Examiner 	correction filed, which has be	een approved by the Examiner.
Identifying indicia such as the application number (see 37 CFR 1 of each sheet. The drawings should be filed as a separate paper		
9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR T		
Attachment(s)	\mathbf{e}_{i}	
 1 ☐ Notice of References Cited (PTO-892) 3 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5 ☐ Information Disclosure Statements (PTO-1449), Paper No. 15 7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	4☐ Interview Summa 5. 6☐ Examiner's Amer	al Patent Application (PTO-152) ary (PTO-413), Paper No adment/Comment ment of Reasons for Allowance
	SUPERTEC	GARY KUNZ VISORY PATENT EXAMINER INVOLOGY CENTER 1000

Application/Control Number: 09/604,938

Art Unit: 1647

REASON FOR ALLOWANCE

Detailed Action

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 20 November 2002 (Paper No. 17) has been entered.

Status of Application, Amendments and/or Claims

The information disclosure statement filed 03 September 2002 (Paper No. 15) was received and complies with the provisions of 37 CFR §§1.97 and 1.98. It has been placed in the application file and the information referred to therein has been considered as to the merits.

The amendment filed 20 November 2002 (Paper No. 18) has been entered in full.

The Pascal Sebastian Bailon declaration, now titled "Declaration II of Pascal S. Bailon", filed under 37 CFR 1.132, has been entered (20 November 2002, Paper No. 19).

Reasons for Allowance: Applicant has submitted arguments, references and Declaration II of Pascal S. Bailon to show the unexpected results of the instant

Application/Control Number: 09/604,938

Page 3

Art Unit: 1647

invention. Applicant states that it is the specific nature of each of the components of this tri-part conjugate i.e. the particular protein, with a particular linking agent and PEG moiety which produce the new and unexpected beneficial therapeutic properties. Applicant submits patents to demonstrate that it is unpredictable whether the tri-part conjugate of a protein, linker and PEG moiety will produce a product that will have therapeutically beneficial properties. The patents submitted also demonstrate that various linking groups are not equivalent in producing therapeutically beneficial PEG/protein conjugates.

Applicant has argued that the art does not teach or fairly suggest a reasonable expectation of success in the combined references employed in the 103(a) rejection. In view of the evidence, the instant claims have been allowed. The Declaration II of Pascal S. Bailon and the newly submitted references do not obviate the allowance of the instant claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 09/604,938

Art Unit: 1647

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Regina M. DeBerry whose telephone number is (703) 305-6915. The examiner can normally be reached on Mondays-Fridays 8:00 a.m. - 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (703) 308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

All Post-Allowance Correspondence concerning this application can be faxed to The Office of Patent Publications at (703) 308-5065.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

RMD

January 24, 2003

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1800